“In terms of outbound deals in pharma, with the top 10-15 players, certainly we are seeing an increase in appetite,” said Subhakanta Bal, managing director and head of healthcare and consumer (India) at Rothschild & Co. “You could say that it is an evolution for the Indian pharma sector, where larger companies are increasingly looking at doing outbound deals.”
Overseas acquisitions: Indian drugmakers shop for deals abroad as they move away from generics
Date:
More like thisRelated
When reinvestment fails: A look at the tax implications of unused Capital Gains Account Scheme funds
LivemintFor about a decade, Livemint—News Desk has been a...
Aditya Birla Group seen as front-runner in $1.7-billion-plus deal for Shell’s Sprng Energy: report
Kumar Mangalam Birla-led Aditya Birla Group is likely to...
US stocks today: Dow soars 800 points to hit record as Iran optimism offsets chip slump, weak jobs data
Wall Street advanced on Thursday as progress toward ending...
Keir Starmer slams Elon Musk for ‘interfering’ in UK politics amid Henry Nowak controversy
Prime Minister Keir Starmer on Thursday said Elon Musk...